Weekly Analysts’ Ratings Changes for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE: JNJ) has recently received a number of price target changes and ratings updates:

• 7/15/2026 – Johnson & Johnson was given a new $260.00 price target by Stifel Nicolaus.
• 7/13/2026 – Johnson & Johnson had its price target raised by TD Cowen from $250.00 to $300.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $265.00 to $287.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Johnson & Johnson had its price target raised by Bank of America Corporation from $254.00 to $263.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $283.00 to $284.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $285.00 to $298.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Johnson & Johnson was given a new $290.00 price target by HSBC Holdings plc. They now have a “buy” rating on the stock.
• 6/26/2026 – Johnson & Johnson was given a new $270.00 price target by Johnson Rice.
• 6/26/2026 – Johnson & Johnson had its price target raised by Guggenheim from $266.00 to $270.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Johnson & Johnson was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.